Webinars|

Webinar: The Faster Path to Market

Press Release 201802 Webinar

On March 22, 2018, SHL Group will hold a live webinar to discuss how pharmaceutical companies can leverage a preconfigured device technology to bring their innovative drug formulations to market more efficiently.

The webinar, titled “The faster path to market: how pharma can benefit from using a robust and well-defined preconfigured drug delivery device,” will be led by Dr Thomas P Schönknecht, executive director of business development at SHL Group.

With the increase in chronic diseases and the emergence of biological and biosimilar drug formulations, self-injection devices have continued to see strong and consistent growth. More and more pharmaceutical companies are leveraging preconfigured offerings to increase efficiency, reduce costs, and ultimately shorten time-to-market for their novel therapies.

In the webinar, Dr Schönknecht will address this trend while exploring the challenges, opportunities, and key traits of a successful preconfigured device. He will also look at the regulatory considerations that are required in order to support the approval as well as entire lifecycle of the drug product. Join Dr Schönknecht to learn more about how to turn an innovative drug into a winning combination product.

Sign up for the webinar HERE

 

ABOUT THE SPEAKER
Thomas P Schönknecht, PhD
Executive Director, Business Development

2018 Webinar Ts

Thomas Schönknecht is an executive director for Business Development at SHL Group. He has over 20 years’ experience in the pharmaceutical industry, working in various leading roles including project management, research and development, and business development for advanced drug delivery solutions.

Dr. Schönknecht holds a PhD in biophysical chemistry from the Max-Planck-Society and the University Goettingen, Germany and a master’s degree in chemistry from the University Goettingen. He is a frequent speaker, moderator and committee member at conferences regarding drug delivery and packing material science.

About SHL

SHL Group is a world-leading solution provider in the design, development and manufacturing of advanced drug delivery devices such as autoinjectors, pen injectors and advanced inhaler systems. We also offer core competencies and services in the fields of medtech and patient care solutions. With locations in Taiwan, Switzerland, Sweden, China and the US, our experienced engineers and designers develop product enhancements as well as breakthrough drug delivery and patient care solutions for pharma and biotech clients globally. Significant investment in R&D has enhanced our broad pipeline of next-generation drug delivery systems that support ongoing innovations in drug development and digital healthcare. This includes advanced reusable and disposable injectors that can accommodate high volume and high viscosities and can be enhanced through digital implementations.

With over 4,800 employees worldwide, SHL Group consists of several distinct group companies:

SHL Medical designs, develops and manufactures advanced drug delivery devices, as well as provides final assembly, labeling and packaging services for leading pharmaceutical and biotech companies across the globe.

SHL Healthcare develops and manufactures equipment solutions for home, hospital and long term care use.

SHL Technologies provides contract manufacturing and engineering services for the production of complex medtech and industrial products.

For additional information, visit www.shl.group

 

Share:

Related News